在代谢功能障碍的成年人中，MAF-5 评分预测了肝纤维化的风险（AUC 范围为 0.73 至 0.81）。

In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81).

机构信息

Arcadia, California, USA (J.K.).

出版信息

Ann Intern Med. 2024 Oct;177(10):JC119. doi: 10.7326/ANNALS-24-02090-JC. Epub 2024 Oct 1.

DOI:10.7326/ANNALS-24-02090-JC

PMID:39348699

Abstract

van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Gastroenterology. 2024;167:357-367.e9. 38513745.

摘要

van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. 《胃肠病学》. 2024;167:357-367.e9. 38513745.

相似文献

In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81).在代谢功能障碍的成年人中，MAF-5 评分预测了肝纤维化的风险（AUC 范围为 0.73 至 0.81）。

Ann Intern Med. 2024 Oct;177(10):JC119. doi: 10.7326/ANNALS-24-02090-JC. Epub 2024 Oct 1.

Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.代谢相关脂肪性肝病-5（MAF-5）评分预测代谢相关脂肪性肝病患者的肝脏纤维化风险和结局。

Gastroenterology. 2024 Jul;167(2):357-367.e9. doi: 10.1053/j.gastro.2024.03.017. Epub 2024 Mar 19.

Comments on "Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction".关于《代谢功能障碍相关纤维化5（MAF-5）评分预测代谢功能障碍普通人群的肝纤维化风险及预后》的评论

Gastroenterology. 2024 Dec;167(7):1504-1505. doi: 10.1053/j.gastro.2024.07.043. Epub 2024 Sep 7.

One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.一步法无创诊断高危人群代谢相关脂肪性肝炎及纤维化。

United European Gastroenterol J. 2024 Sep;12(7):919-929. doi: 10.1002/ueg2.12589. Epub 2024 Aug 4.

A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.用于检测代谢功能障碍相关脂肪性肝病患者显著纤维化的非侵入性检测组合并不优于单独使用磁共振弹性成像。

Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.

A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease.代谢组衍生评分可预测代谢功能障碍相关脂肪性肝炎及肝病死亡率。

J Hepatol. 2025 May;82(5):781-793. doi: 10.1016/j.jhep.2024.10.015. Epub 2024 Oct 16.

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.基于肝活检的验证、确认和比较新型及传统非酒精性脂肪性肝病无创性诊断指标的诊断效能：一项多中心大样本研究。

Metabolism. 2023 Oct;147:155666. doi: 10.1016/j.metabol.2023.155666. Epub 2023 Jul 30.

High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.代谢相关脂肪性肝病患者肝纤维化评分高与导管消融术后不良的心房重构和心房颤动复发相关。

Front Endocrinol (Lausanne). 2022 Aug 31;13:957245. doi: 10.3389/fendo.2022.957245. eCollection 2022.

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.低至中度饮酒与代谢功能障碍相关脂肪性肝病患者的纤维化增加有关。

J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4.

Significant Association Between Left Ventricular Diastolic Dysfunction, Left Atrial Performance and Liver Stiffness in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.代谢综合征和非酒精性脂肪性肝病患者左心室舒张功能障碍、左心房功能与肝硬度之间的显著关联

Diabetes Metab Syndr Obes. 2021 Apr 9;14:1535-1545. doi: 10.2147/DMSO.S300450. eCollection 2021.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在代谢功能障碍的成年人中，MAF-5 评分预测了肝纤维化的风险（AUC 范围为 0.73 至 0.81）。

In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81).

机构信息

出版信息

相似文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献